Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors

Bioorganic & Medicinal Chemistry Letters
2006.0

Abstract

A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bcr-Abl-positive leukemia cell line K562. About ten 3-halogenated and 3-trifluoromethylated benzamide derivatives were identified as highly potent Bcr-Abl kinase inhibitors. One of these, NS-187 (9b), is a promising new candidate Bcr-Abl inhibitor for the therapy of STI-571-resistant chronic myeloid leukemia.

Knowledge Graph

Similar Paper

Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors
Bioorganic & Medicinal Chemistry Letters 2006.0
Design, Synthesis, and Biological Evaluation of 3-(1H-1,2,3-Triazol-1-yl)benzamide Derivatives as Potent Pan Bcr-Abl Inhibitors Including the Threonine<sup>315</sup>→Isoleucine<sup>315</sup> Mutant
Journal of Medicinal Chemistry 2012.0
Synthesis and biological evaluation of novel aromatic amide derivatives as potential BCR-ABL inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2023.0
Design, synthesis, and biological activity of 4-(imidazo[1,2- b ]pyridazin-3-yl)-1 H -pyrazol-1-yl-phenylbenzamide derivatives as BCR–ABL kinase inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2016.0
Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR–ABL kinase
Bioorganic &amp; Medicinal Chemistry Letters 2012.0
Design, synthesis and evaluation of (E)-α-benzylthio chalcones as novel inhibitors of BCR-ABL kinase
Bioorganic &amp; Medicinal Chemistry 2010.0
Hybrid compounds as new Bcr/Abl inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2011.0
Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives
Bioorganic &amp; Medicinal Chemistry Letters 1997.0
Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR–ABL kinase inhibitors
Bioorganic &amp; Medicinal Chemistry 2015.0
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents
Bioorganic &amp; Medicinal Chemistry Letters 2008.0